NO20004667D0 - Farmasøytiske formuleringer omfattende et 2-[[(2- pyridinyl)metyl]sulfinyl]benzimidazol med anti-magesÕraktivitet og en fremgangsmÕte for fremstilling av en slik formulering - Google Patents

Farmasøytiske formuleringer omfattende et 2-[[(2- pyridinyl)metyl]sulfinyl]benzimidazol med anti-magesÕraktivitet og en fremgangsmÕte for fremstilling av en slik formulering

Info

Publication number
NO20004667D0
NO20004667D0 NO20004667A NO20004667A NO20004667D0 NO 20004667 D0 NO20004667 D0 NO 20004667D0 NO 20004667 A NO20004667 A NO 20004667A NO 20004667 A NO20004667 A NO 20004667A NO 20004667 D0 NO20004667 D0 NO 20004667D0
Authority
NO
Norway
Prior art keywords
sulfinyl
benzimidazole
pyridinyl
formulation
methyl
Prior art date
Application number
NO20004667A
Other languages
English (en)
Other versions
NO20004667L (no
Inventor
Kristian Lund Henriksen
Helle Kann
Karen Eichstedt Soerensen
Soeren Bols Pedersen
Original Assignee
Gea Farmaceutisk Fabrik As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20004667(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gea Farmaceutisk Fabrik As filed Critical Gea Farmaceutisk Fabrik As
Publication of NO20004667D0 publication Critical patent/NO20004667D0/no
Publication of NO20004667L publication Critical patent/NO20004667L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20004667A 1998-03-20 2000-09-19 Farmasoytisk formulering omfattende et 2-[[(2-pyridinyl)metyl]sulfinyl]benzimidazol med anti-ulcusaktivitet, og en fremgangsmate for fremstilling av en slik formulering NO20004667L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK199800397A DK173431B1 (da) 1998-03-20 1998-03-20 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
PCT/DK1999/000137 WO1999048498A1 (en) 1998-03-20 1999-03-17 Pharmaceutical formulation comprising a 2- [[(2- pyridinyl) methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation

Publications (2)

Publication Number Publication Date
NO20004667D0 true NO20004667D0 (no) 2000-09-19
NO20004667L NO20004667L (no) 2000-11-09

Family

ID=8093069

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004667A NO20004667L (no) 1998-03-20 2000-09-19 Farmasoytisk formulering omfattende et 2-[[(2-pyridinyl)metyl]sulfinyl]benzimidazol med anti-ulcusaktivitet, og en fremgangsmate for fremstilling av en slik formulering

Country Status (20)

Country Link
US (1) US6391342B1 (no)
EP (1) EP1061920B1 (no)
AR (1) AR014753A1 (no)
AT (1) ATE218863T1 (no)
AU (1) AU744596B2 (no)
CA (1) CA2323536C (no)
CZ (1) CZ291943B6 (no)
DE (1) DE69901804T2 (no)
DK (2) DK173431B1 (no)
EA (1) EA002502B1 (no)
ES (1) ES2177246T3 (no)
HU (1) HU226580B1 (no)
IS (1) IS2265B (no)
NO (1) NO20004667L (no)
NZ (1) NZ507115A (no)
PL (1) PL192437B1 (no)
TR (1) TR200002696T2 (no)
TW (1) TW529951B (no)
WO (1) WO1999048498A1 (no)
ZA (1) ZA200004757B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526022T1 (de) 1998-04-20 2011-10-15 Eisai R&D Man Co Ltd Stabilisierte zusammenstellungen die benzimidazole enthalten
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2376202C (en) 1999-06-07 2008-11-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
WO2001032185A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004089333A2 (en) * 2003-02-28 2004-10-21 Cadila Healthcare Limited A stable benzimidazole formulation
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
CN1874764B (zh) * 2003-10-10 2012-08-01 埃法尔姆公司 含有银杏提取物的持续释放微粒及其制备方法
US20070141150A1 (en) * 2003-12-30 2007-06-21 Raghupathi Kandarapu Pharmaceutical composition
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
JP2007526319A (ja) * 2004-03-03 2007-09-13 テバ ファーマシューティカル インダストリーズ リミティド 酸不安定性薬物を含んでなる安定な医薬組成物
EP1746980B1 (en) 2004-05-07 2011-11-02 Nycomed GmbH Pharmaceutical dosage form comprising pellets as well as its manufacturing process
JP5563735B2 (ja) * 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
WO2007075381A2 (en) * 2005-12-16 2007-07-05 Tap Pharmaceutical Products, Inc. Pharmaceutical compositions of ilaprazole
WO2007100984A2 (en) * 2006-02-24 2007-09-07 Allergan, Inc. Beads containing pyridin-sulfinyl benzoimidazole sulfonyl phenoxy acetate derivatives
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20100239681A1 (en) * 2009-03-20 2010-09-23 Biokey, Inc. Controlled Release Particulates Containing Water-Insoluble Drug
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN103202820B (zh) * 2012-01-11 2016-03-30 浙江亚太药业股份有限公司 一种稳定的兰索拉唑肠溶胶囊及其制备方法
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018098501A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
ES2024993A6 (es) 1990-12-31 1992-03-01 Genesis Para La Investigacion Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.
TW209174B (no) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
SE9200858L (sv) 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
FR2692146B1 (fr) 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
ES2087823B1 (es) 1994-07-13 1997-02-16 Estudes Et Richerches Pharma E Formulacion de microgranulos gastroresistentes de omeprazol y su procedimiento de fabricacion.
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
CH687810A5 (de) 1995-05-24 1997-02-28 Mepha Ag Pelletformulierung mit Omeprazol.
ATE262332T1 (de) 1995-09-21 2004-04-15 Pharma Pass Ii Llc Lansoprazolhaltige arzneizusammensetzung und herstellungsverfahren
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
PT101826A (pt) 1996-02-06 1997-09-30 Medinfar Produtos Farmaceutico Processo para a preparacao de microgranulos contendo omeprazole
WO1998040377A1 (en) 1997-03-07 1998-09-17 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose

Also Published As

Publication number Publication date
ES2177246T3 (es) 2002-12-01
ZA200004757B (en) 2001-05-30
PL192437B1 (pl) 2006-10-31
DE69901804D1 (de) 2002-07-18
EP1061920A1 (en) 2000-12-27
DK39798A (da) 1999-09-21
TR200002696T2 (tr) 2000-12-21
NO20004667L (no) 2000-11-09
IS2265B (is) 2007-07-15
EA002502B1 (ru) 2002-06-27
DE69901804T2 (de) 2002-12-12
AR014753A1 (es) 2001-03-28
CA2323536C (en) 2009-05-19
DK173431B1 (da) 2000-10-23
DK1061920T3 (da) 2002-07-15
EP1061920B1 (en) 2002-06-12
CZ291943B6 (cs) 2003-06-18
HU226580B1 (en) 2009-04-28
US6391342B1 (en) 2002-05-21
PL342840A1 (en) 2001-07-16
CZ20003458A3 (cs) 2001-03-14
HUP0101178A2 (hu) 2001-08-28
ATE218863T1 (de) 2002-06-15
AU2714899A (en) 1999-10-18
AU744596B2 (en) 2002-02-28
WO1999048498A1 (en) 1999-09-30
CA2323536A1 (en) 1999-09-30
TW529951B (en) 2003-05-01
NZ507115A (en) 2002-09-27
IS5628A (is) 2000-09-13
EA200000970A1 (ru) 2001-02-26

Similar Documents

Publication Publication Date Title
NO20004667D0 (no) Farmasøytiske formuleringer omfattende et 2-[[(2- pyridinyl)metyl]sulfinyl]benzimidazol med anti-magesÕraktivitet og en fremgangsmÕte for fremstilling av en slik formulering
NO995809L (no) Farmasoeytisk formulering av omeprazol
DE60100186D1 (de) Orale pharmazeutische formulierungen von benzimidazolderivaten und verfahren zu ihrer herstellung
EE200100714A (et) Farmatseutiliste ravimvormide pihustamissüsteemidja -meetodid
NO20003051D0 (no) Metode for administrering av AspB28-humant insulin
NO20005430D0 (no) 1-[(1-substituerte-4-piperidinyl)metyl]-4-piperidinderivater, fremgangsmÕter for fremstilling av disse, medisinske preparater inneholdende dem, og mellomprodukter
RS50245B (sr) Gastroprotektovane mikrogranule omeprazola, postupak za proizvodnju i farmaceutski preparati
EE200100259A (et) Moksifloksatsiini farmatseutiline preparaat
DE60020501D1 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
PL343936A1 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
EE200300371A (et) Peroraalselt ja paikselt manustatavad farmatseutilised kopmositsioonid
DK122391A (da) Terapeutisk aktiv, substitueret benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
NO994340D0 (no) FremgangsmÕte for fremstilling av 2-[[(2-pyridinyl)metyl]sulfinyl]-1H-benzimidazoler samt nye forbindelser til anvendelse for dette formÕl
FR2793688B1 (fr) Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
NO994209D0 (no) FremgangsmÕte for fremstilling av 2-[[(2-pyridinyl)metyl]sulfinyl]-1H-benzimidazoler og nye forbindelser til anvendelse for dette formÕl
PT1206253E (pt) Preparacoes farmaceuticas solidas contendo nanossois de quitosano e metodo de preparacao
NO20015848D0 (no) Polymorfer av et krystallinsk azabicyclo(2,2,2)oktan-3- amincitrat og farmasöytiske preparater derav
NO20020777D0 (no) Farmasöytiske preparater inneholdende derivater og fremgangsmåte for fremstilling derav
IT1276684B1 (it) Formulazioni idrosolubili di collagenasi stabilizzata e procedimento per la loro preparazione
PL352041A1 (en) Derivatives of isochynoline, pharmaceutical compositions containing these derivatives and method of obtaining an active substance
NO20021527D0 (no) Pyrimidinderivater, fremgangsmåte for fremstilling av derivatene og legemidler inneholdende de samme som den aktivebestanddel
NO20015488D0 (no) 14<beta>-H-steroler, farmasöytiske preparater som omfatter dem, og anvendelse av disse derivatene til fremstilling avmeioseregulerende medikamenter
SI1077703T1 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
ITFI980203A0 (it) Metodo e dispositivo per la somministrazione di farmaci
AU4261196A (en) Use of 2-(4-(azolylbutyl)piperazinyl-(methyl)benzimidazole derivatives for preparing drugs for treating or preventing asthma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application